Jubilant Pharmova Limited has informed the Exchange that Record date for the purpose of Dividend is 25-Jul-2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Pharmova's board approved audited consolidated and standalone financial results for Q4 and FY ended March 31, 2025, with statutory auditors Walker Chandiok & Co LLP issuing an unmodified opinion. The board recommended a final dividend of Rs. 5 per share (500% on face value of Re. 1), totaling about Rs. 796 million, with July 25, 2025 fixed as the record date. Consolidated revenue from operations rose to Rs. 72,345 million in FY25 from Rs. 67,029 million in FY24, while net profit surged to Rs. 8,363 million from Rs. 727 million, with EPS jumping to Rs. 52.99 from Rs. 4.87. Results were significantly boosted by a one-time net gain of Rs. 6,715 million from the sale of its stake in SOFIE Biosciences, partly offset by closure costs at its Salisbury facility, inventory provisions, and Montreal remediation expenses. The company also reduced long-term borrowings sharply to Rs. 21,503 million from Rs. 31,671 million using the SOFIE proceeds.
Shareholders benefit from a strong 500% dividend payout and substantially higher earnings, though the headline profit spike is largely driven by the one-time SOFIE divestment gain rather than core operations. The debt reduction and positive operating cash flow of Rs. 10,721 million strengthen the balance sheet, likely supporting positive sentiment on the stock.